PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 26 filers reported holding PHARVARIS N V in Q4 2022. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $67,450,233 | +32.8% | 3,231,923 | 0.0% | 0.27% | +31.7% |
| Q2 2023 | $50,773,510 | +100.9% | 3,231,923 | 0.0% | 0.21% | +74.8% |
| Q1 2023 | $25,273,638 | -30.5% | 3,231,923 | 0.0% | 0.12% | -34.6% |
| Q4 2022 | $36,359,134 | +81.3% | 3,231,923 | +29.4% | 0.18% | +95.7% |
| Q3 2022 | $20,050,000 | -63.6% | 2,496,923 | +0.2% | 0.09% | -63.1% |
| Q2 2022 | $55,071,000 | +18.7% | 2,491,923 | +0.5% | 0.25% | +34.0% |
| Q1 2022 | $46,382,000 | +19.4% | 2,480,319 | +1.0% | 0.19% | +67.9% |
| Q4 2021 | $38,847,000 | -5.8% | 2,455,536 | +2.7% | 0.11% | -0.9% |
| Q3 2021 | $41,254,000 | -5.1% | 2,391,517 | 0.0% | 0.11% | -14.4% |
| Q2 2021 | $43,454,000 | -36.0% | 2,391,517 | -1.2% | 0.13% | -34.7% |
| Q1 2021 | $67,910,000 | – | 2,420,155 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $60,770,000 | 8.21% |
| venBio Partners LLC | 2,303,310 | $42,911,000 | 5.06% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $59,255,000 | 3.88% |
| Foresite Capital Management V, LLC | 364,142 | $6,784,000 | 2.67% |
| VR Adviser, LLC | 902,882 | $16,821,000 | 2.04% |
| Cormorant Asset Management, LP | 744,863 | $13,634,000 | 0.46% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,032,757 | $19,240,000 | 0.34% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $45,087,000 | 0.32% |
| Opaleye Management Inc. | 79,837 | $1,487,000 | 0.25% |
| Avidity Partners Management LP | 400,000 | $7,452,000 | 0.20% |